# Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)

> **NCT03241927** · PHASE2 · TERMINATED · sponsor: **Nina Bhardwaj** · enrollment: 1 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03241927
- **Lead sponsor:** Nina Bhardwaj
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-20
- **Primary completion:** 2018-06-06
- **Final completion:** 2018-06-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** difficult enrollment
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03241927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03241927, "Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03241927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*